Hong Kong stock anomaly | MIRXES-B (02629.HK) rose nearly 15% at the close. Its core product is the world's first approved miRNA gastric cancer early screening kit.

According to the Securities Times APP, the newly listed stock MIRXES-B (02629.HK) rose by nearly 15% in the afternoon session, reaching a high of 34.8 Hong Kong dollars to set a new record high, an increase of nearly 50% from the IPO price. As of the time of writing, it has risen by 13.72% to 34.4 Hong Kong dollars, with a trading volume of 79.3835 million Hong Kong dollars.